LYN - SPR Binding Assay

Our service for comprehensive kinetic characterization of your small molecule kinase inhibitors

Theoretical background: Lyn is a Src family kinase primary expressed in hematopoietic cells, predominantly in B cells. The modular structure is formed by an N-terminal tail, a Src homology 3 (SH3) domain, a SH2 domain, the catalytic core and a C-terminal negative regulatory domain. Lyn is associated with the BCR in resting cells and serves upon antigen binding and BCR aggregation to phosphorylate tyrosine containing ITAM motifs on Ig-╬▒/╬▓. Furthermore, Lyn activation results in CD22 phosphorylation and the recruitment and activation of the tyrosine phosphatase SHP-1, which downmodulates BCR-mediated signaling. Lyn is an important candidate target for specific therapy of prostate cancer, colon cancer and acute myeloid leukemia.


Lyn and inhibitors: The pyrazolo-pyrimidines PP1 and the related compound PP2 are widely used ATP competitive Src family kinase inhibitors showing a good potency against various kinases as Src, Lck, Lyn (PP2 IC50 = 9 nM [1]) and Fyn. SU6656 is a cell permeable and potent inhibitor of Lyn (IC50 = 35 nM [1]), Fyn, Yes and Src but a rather poor inhibitor of Lck. Dasatinib, initially isolated as a dual Src/Abl inhibitor has a high affinity against Abl, Yes, Lyn (KD = 0.57 nM [2]) and Lck too and is used in several clinical trials.


Figure: Real-time kinetic analysis of kinase inhibitor Dasatinib binding to LYN using surface plasmon resonance.

[1] Williams NK et al. (2009) J Biol Chem. 2009 Jan 2;284(1):284-91.

[2] Karaman MW et al. (2008) Nat Biotechnol. 2008 Jan;26(1):127-32.


Please contact our application specialists to obtain more information and an individual quote tailored to your specific needs.

BIAFFIN GmbH & Co KG | Heinrich-Plett-Str. 40 | D-34132 Kassel | Germany
Tel.: +49 (0) 561-804 4661 | Fax: +49 (0) 561-804 4665 |

We value your privacy

In order to optimize our website for you and to be able to continuously improve it, we use cookies. Further information is available in our Data Protection Statement. Here you can find our Legal Information.